Email me (check my profile please), no PM\DM in Bluesky...

Many kudos to the rest of the team as well, including Laura Heiser team (OHSU), Pacific Northwest National Laboratory scientists, Matthew Hoare (Cambridge University) and former lab members.

Huge thanks to Cancer Research UK (CRUK) for jumpstarting this project back in 2020, and to OHSU CDCB T32 support to Tahereh Ziglari, the lead scientist of this study. This work would have not been possible without her dedication and hard work.

These findings support the use of senescent cell EVs as a novel immunotherapy to prevent or treat cancer #relapse.

#aging #SCC #headandneck #exosomes

We found that senescent cells release lots of EVs, which recruit immune cell types involved in antigen presentation. Senescent cell EVs seem to support immune synapse formation with CD4 #Tcells, and both were required to ultimately remove senescent cells and avoid tumor recurrence.

I do, but it looks like I may not be eligible based on time from PhD? Please keep me posted if other opportunities arise!

How about cancer immunology? I may be interested!

3. What about the subcapsular sinus? What differences do you observe there between NN and NP?

2. I understand segmentation may have been limiting, with only 35k cells per section? 2.5M over 70 samples? Unfortunately that is a common limitation of current analysis pipelines, it is unclear how this may impact the results. Thoughts?